HRQOL with enzalutamide for metastatic hormone-sensitive prostate cancer in the ENZAMET trial

The multinational phase III ENZAMET trial evaluated addition of enzalutamide to standard care for patients with metastatic, hormone-sensitive prostate cancer, and found that enzalutamide improved overall survival as was previously reported. Now publised HRQOL analysis of the trial showed that enzalutamide compared with control was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not overall health and quality of life (OQHL). Enzalutamide was associated with improved deterioration-free survival for OQHL, physical function, and cognitive function because delays in disease progression outweighed early deteriorations in these aspects of HRQOL.